P2Y12 Inhibitors Monotherapy in Patients Undergoing Complex vs Non-Complex Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials
Authors' conclusion
Patients undergoing complex PCI may derive more benefit and less harm from P2Y12i monotherapy after early aspirin withdrawal compared with standard DAPT.
Study context
- Population
- Patients undergoing complex vs noncomplex percutaneous coronary intervention (PCI)
- Participants
- 31,627 patients5 trials
- Comparison
- P2Y12 inhibitors (P2Y12i) monotherapy after short dual antiplatelet therapy (DAPT) vs standard DAPT, by PCI complexity
- Outcome
- MI, by PCI complexity (subgroup analysis)
Methodological detailsrandom effects models
- Random effects models
Pooled result
As reported in the abstract
P2Y12i monotherapy vs Standard DAPTHazard ratio (95% CI)P value
Complex PCI
0.77(0.60–0.99)
P = 0.042Noncomplex PCI
1.09(0.90–1.30)
P = 0.382Safety
Major bleeding, by PCI complexity
- Significantly reduced by P2Y12i monotherapy, consistent in complex and noncomplex PCI
- P-interaction = 0.699
Original publication
P2Y12 Inhibitors Monotherapy in Patients Undergoing Complex vs Non-Complex Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Trials. Am Heart J. Published 8 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →